1. Introduction {#s0005}
===============

While amyotrophic lateral sclerosis (ALS) is a clinically and genetically heterogeneous neurodegenerative condition, patients with ALS have a relatively stereotyped disease trajectory dominated by relentlessly progressive motor disability and ultimately respiratory compromise. The core neuroimaging signature of ALS includes motor cortex, brainstem, corticospinal tract, and spinal cord degeneration. Subcortical grey matter degeneration has also been observed both post mortem and in vivo ([@b0605]). Thalamus pathology in ALS has been evaluated by dedicated structural, metabolic, and functional imaging studies ([@b0345], [@b0145], [@b0520], [@b0340], [@b0575]). The thalamus however is typically evaluated as a single structure in ALS. Overall thalamic atrophy has been identified by both neuroimaging ([@b0345], [@b0365], [@b0125]) and post mortem histopathology studies in ALS ([@b0390]), but the involvement of specific nuclei has not been comprehensively characterised to date. The thalamus comprises over 60 cytoarchitectonically distinct nuclei with unique cortical connectivity patterns ([@b0055]), physiological functions, ([@b0080]) embryonic origin, ([@b0065]) and vascular supply ([@b0500]). The risk of evaluating the entire thalamus as a whole is averaging pathological change across affected and unaffected regions. Several radiological approaches exist to segment the thalamus; it may be parcellated based on cortical connectivity patterns ([@b0055], [@b0290], [@b0635]) or anatomically, based on the histological data ([@b0265]). The few existing thalamus studies in ALS segmented the thalamus based on cortical projection patterns ([@b0575], [@b0035]) and not anatomically, which would allow the systematic assessment of specific nuclei.

Given the strikingly focal cortical grey matter signatures observed in both ALS ([@b0340]) and PLS ([@b0150]) we hypothesised that similarly selective thalamic involvement may be detected if thalamic nuclei are appraised individually. Irrespective of the underlying genotype, co-existence of cognitive deficits, familial or sporadic presentation, limb weakness and bulbar impairment are pathognomonic clinical features of ALS ([@b0300]) which can be linked to motor cortex and spinal cord degeneration on imaging ([@b0480]). Based on clinical and radiological observations, it is increasingly clear that extra-pyramidal degeneration also contributes to motor disability in ALS ([@b0465], [@b0200]). Connectivity-based thalamic segmentation in ALS reveals focal degeneration in thalamic regions projecting to motor areas ([@b0035]) and frontotemporal regions ([@b0575]). Accordingly, we hypothesised that thalamic pathology in ALS preferentially involves nuclei mediating motor function such as the ventral anterior and ventral lateral nuclei.

While GGGGCC hexanucleotide expansions in *C9orf72* in ALS have been previously linked to orbitofrontal ([@b0220]); opercular ([@b0030]), cingulate ([@b0145]) and temporal lobe alterations ([@b0225]), widespread extra-motor ([@b0610]) and subcortical grey matter changes ([@b0025]) are also readily observed in *C9orf72* negative sporadic ALS patients. The *C9orf72* genotype has also been linked to thalamus pathology in ALS ([@b0145], [@b0025]), but that thalamic signature of C9orf72-associated ALS has not been characterised at a nuclear level. A recent large FTD study ([@b0075]) identified that *C9orf72* hexanucleotide repeat carriers exhibit preferential pulvinar atrophy, which is thought to be unique to the genotype. Based on the available FTD literature ([@b0075], [@b0070], [@b0355], [@b0270]), one of the objectives of this study is to examine if *C9orf72* mutation carriers in ALS exhibit distinctive patterns of thalamic involvement different from sporadic ALS patients. As GGGGCC hexanucleotide repeat expansions in ALS are associated with neuropsychological deficits ([@b0115]), we hypothesised that *C9orf72* positive ALS patients may exhibit preferential degeneration in thalamic nuclei mediating cognitive functions.

In contrast to ALS, there is a striking paucity of both imaging and post mortem studies in PLS ([@b0150]). PLS is associated with longer survival than ALS ([@b0250]) and the clinical picture is dominated by upper motor neuron dysfunction ([@b0230]). Extra-motor ([@b0170]) and extra-pyramidal ([@b0315]) manifestations have been sporadically reported in PLS, but thalamic involvement has not been systematically characterised to date in vivo. As clinical heterogeneity is less marked in PLS than ALS, we hypothesised that focal changes will be captured in the ventral anterior and ventral lateral nuclei.

While the clinical symptoms of ALS and PLS are dominated by limb weakness, bulbar impairment and respiratory weakness, sensory deficits have also been reported, captured by electrophysiology studies and sensory tract involvement detected on spinal imaging ([@b0260], [@b0490]). Patients with ALS often report paraesthesiae, but frank nociceptive, thermoceptive or proprioceptive deficits are seldom detected on clinical assessment ([@b0560]). The anatomical segmentation of the thalamus into specific nuclei permits the targeted assessment of ventral posterolateral nuclei which mediate somatosensory information from the contralateral face and the ventral medial nuclei conveying somatosensory information from the contralateral trunk and limbs.

Building on accruing evidence of overall thalamic involvement in ALS, the main objective of this study was the characterisation of regional thalamic pathology in sporadic, *C9orf72* negative ALS at a nuclear level. An additional objective was to evaluate if PLS and *C9orf72* positive ALS patients have distinctive thalamic signatures. Based on the review of the literature, we hypothesised, that the 'global' thalamus pathology reported by previous imaging studies in ALS is driven by focal changes in susceptible nuclei.

2. Methods {#s0010}
==========

2.1. Ethics statement {#s0015}
---------------------

All aspects of this study, including recruitment, data management, consent forms and information leaflets were approved by the institutional ethics committee (Beaumont Hospital, Dublin, Ireland), in accordance with the 1964 Helsinki declaration and its later amendments. Study participants provided informed consent prior to inclusion.

2.2. Participants {#s0020}
-----------------

Patients were recruited between September 2017 and September 2020. Hundred patients with ALS, 33 patients with PLS and 117 healthy controls were included in this study. PLS patients were diagnosed based on the Gordon criteria ([@b0250]) Participating ALS patients had 'probable' or 'definite' ALS according to the El Escorial criteria ([@b0095]). Exclusion criteria included a known history of traumatic brain injury, cerebrovascular events, neuroinflammatory conditions, neoplastic conditions, and inability to undergo MRI scanning due to metallic devices such as baclofen pumps or pacemakers. Known claustrophobia or orthopnoea were other exclusion criteria. The demographic and clinical profile of each patient was carefully recorded; motor disability was assessed by the revised ALS functional rating scale (ALSFRS-r) ([@b0120]), the Edinburgh Cognitive ALS Screen (ECAS) ([@b0015]) was administered for cognitive assessment using population-based normative values ([@b0450]) and the diagnosis of co-morbid FTD was established based on the revised Strong criteria ([@b0550]). The healthy controls of the study were unrelated to the participating patients and had no known neurological or psychiatric conditions, previous head injuries or a family history of neurodegenerative conditions.

2.3. Neuroimaging methods {#s0025}
-------------------------

T~1~-weighted images were acquired with a 3D Inversion Recovery prepared Spoiled Gradient Recalled echo (IR-SPGR) pulse sequence on a 3 Tesla Philips Achieva system using an 8-channel receive-only head coil. The following pulse sequence parameters were used; field-of-view (FOV): 256 × 256 × 160 mm, spatial resolution: 1 mm^3^, TR/TE = 8.5/3.9 ms, TI = 1060 ms, flip angle = 8°, SENSE factor = 1.5, acquisition time: 7 min 30 s.

2.4. TIV volumes {#s0030}
----------------

Total intracranial volume (TIV) was estimated for each study participant to be used as a covariate in comparative statistical models. TIV was calculated by adding grey matter, white matter and CSF volume estimates. Registration and tissue type segmentation was carried out in FMRIB's FSL environment. Following skull-stripping ([@b0535]) and individual quality verification, each subject image was linearly aligned to MNI152 standard space using FMRIB\'s Linear Image Registration Tool (FLIRT) ([@b0285]). Tissue-type segmentation was performed using FMRIB\'s Automated Segmentation Tool (FAST) ([@b0640]) which accounts for spatial intensity variations. The inverse of the determinant of the affine registration matrix was calculated and multiplied by the size of the template for tissue-type volume estimation.

2.5. Thalamic segmentation {#s0035}
--------------------------

A Bayesian inference was used to segment the thalamus into 25 sub-regions as described by Iglesias at al. using a probabilistic atlas developed based on histological data in the FreeSurfer analysis suite ([@b0265]) ([Fig. 1](#f0005){ref-type="fig"}). The thalamus was parcellated into the following nuclei in each hemisphere: antero-ventral (AV), latero-dorsal (LD), lateral posterior (LP), ventral anterior (VA), ventral anterior magnocellular (VA mc), ventral lateral anterior (VLa), ventral lateral posterior (VLp), ventral posterolateral (VPL), ventromedial (VM), central medial (CeM), central lateral (CL), paracentral (Pc), centromedian (CM), parafascicular (Pf), paratenial (Pt), reuniens/medial ventral (MV-re), mediodorsal medial magnocellular (MDm), mediodorsal lateral parvocellular (MDl), lateral geniculate (LGN), medial geniculate (MGN), limitans/suprageniculate (L-SG), pulvinar anterior (PuA), pulvinar medial (PuM), pulvinar lateral (PuL), and pulvinar inferior (PuI). The raw volume estimates of the above nuclei were averaged between left and right and merged into the following 10 core group of nuclei defined based on their distinctive physiological function: "Anteroventral", "Lateral geniculate", "Medial geniculate", "Pulvinar-limitans" (PuA, PuM, PuL, PuI, L-SG), "Laterodorsal", "Lateroposterior", "Mediodorsal-paratenial-reuniens" (MDm, MDl, MV-re, Pt), "Motor hub" (VA, VAmc, VLa, VLp), "Sensory hub" (VPL, VM), "Intralaminar" (CeM, CL, Pc, CM, Pf). "Total thalamic volume" was defined as the mean of the left and right thalamus volume estimates.Fig. 1Atlas-based segmentation of the thalamus; anteroventral (AV), central medial (CeM), central lateral (CL), centromedian (CM), laterodorsal (LD), lateral geniculate (LGN), lateral posterior (LP), limitans/suprageniculate (L-SG), mediodorsal lateral parvocellular (MDl), mediodorsal medial magnocellular (MDm), medial geniculate (MGN), reuniens/medial ventral (MV-re), paracentral (Pc), parafascicular (Pf), pulvinar anterior (PuA), pulvinar inferior (PuI), pulvinar lateral (PuL), pulvinar medial (PuM), ventral anterior (VA), ventral anterior magnocellular (VA mc), ventral lateral anterior (VLa), ventral lateral posterior (VLp), ventromedial (VM), ventral posterolateral (VPL).

2.6. Vertex analyses {#s0040}
--------------------

Surface projected patterns of atrophy were evaluated using vertex analyses. As described previously ([@b0345]), FMRIB's subcortical segmentation and registration tool FIRST ([@b0430]) was utilised to characterise focal thalamic shape deformations. Vertex locations of each participant were projected on the surface of an average thalamic shape template as scalar values, positive value being outside the surface and negative values inside. The average thalamic shape was generated from all participants. Permutation based non-parametric inference was implemented for group comparisons using FMRIB's 'RANDOMISE' module ([@b0620]). The design matrices included demeaned age, gender, education, total intracranial volumes and education as covariates ([@b0620]).

2.7. Region of interest morphometry {#s0045}
-----------------------------------

In order to characterise focal pathology beyond shape deformations and volume reductions in the thalamus, region-of-interest morphometry was performed to explore focal density alterations. FMRIB's software library (FSL) was used for skull removal and tissue-type segmentation. Affine registration was used to align grey-matter partial volume images to the MNI152 standard space. A study-specific grey matter template was then created to which the grey matter images of each subject were non-linearly coregistered. The study specific template was generated by the same number of randomly selected subjects from each study group i.e. 12 C9 + ALS patients, 12 C9- ALS patients, 12 healthy controls and 12 PLS patients to ensure that the template is representative of each study group. A voxelwise generalized linear model and permutation-based non-parametric inference were utilised to evaluate density alterations in a bilateral thalamus mask accounting for age, gender, TIV and education ([@b0620], [@b0395]). The labels of the Harvard-Oxford probabilistic structural atlas ([@b0180]) was used to generate the bilateral thalamus mask.

2.8. Genetics {#s0050}
-------------

All ALS and PLS patients were tested for *C9orf72* repeat expansions and tested for a panel of mutations implicated in ALS and PLS. DNA samples were tested for pathogenic GGGGCC hexanucleotide repeat expansions by repeat-primed PCR using the Applied Biosystems (Foster City, CA, USA) 3130xl Genetic Analyser and visualised using GeneMapper version 4.0. More than 30 hexanucleotide repeats were considered pathological. All patients were also tested for an extensive panel of ALS and PLS associated mutations including *SOD1, ALS2, SETX, SPG11, FUS, VAPB, ANG, TARDBP,* [Fig. 4](#f0020){ref-type="fig"}*, OPTN, ATXN2, VCP, UBQLN2, SIGMAR1, CHMP2B, PFN1, ERBB4, HNRNPA1, MATR3, CHCHD10, UNC13A, DAO, DCTN1, NEFH, PRPH, SQSTM1, TAF15, SPAST, ELP3, LMNB1, SARM1, C21orf2, NEK1, FUS, CHMP2B, GRN, MAPT, PSEN1, PSEN2, TBK1*. Sixty-seven ALS patients and all 33 PLS patients underwent whole genome sequencing ([@b0470]) and the remaining 33 ALS patients underwent target next --generation targeted sequencing ([@b0295]). In addition to *C9orf72* testing and genetic screening for established ALS-causing mutations, PLS patients were also screened for a panel of 70 genes linked to HSP ([@b0205], [@b0305]). ALS patients were stratified based on their *C9orf72* status. Inclusion criteria for the *C9orf72* positive ALS group were patients who carried the GGGGCC repeat expansions but tested negative for other established mutations associated with ALS. Inclusion criteria for the *C9orf72* negative ALS group were patients who tested negative for *C9orf72* hexanucleotide repeat expansions as well as other established mutations associated with ALS. All PLS patients included in this study tested negative for the *C9orf72* repeat expansions as well as mutations associated with ALS and HSP.

2.9. Statistical analysis {#s0055}
-------------------------

The statistical interpretation of demographic and clinical data was conducted using IBM Statistical Product and Service Solutions (SPSS) version 25. Group differences in age, education and ALSFRS-r were examined using multivariate analysis of variance (MANOVA). Differences in gender, handedness, disease onset, and the proportion of patients with cognitive impairment were assessed with Chi-square tests. Intergroup differences in thalamic volumes were also evaluated in SPSS. Assumptions of normality were examined using the Kolmogorov-Smirnov test separately for each group. Since all variables followed a normal distribution, parametric statistics were used. Intergroup differences in thalamic volumes were examined using multivariate analysis of covariance with total intracranial volume (TIV), age, gender and education as covariates. If a significant main effect of group membership was identified (p \< 0.05) for specific thalamic nuclei, post-hoc group comparisons were performed. False discovery rate (FDR-Benjamini Hochberg) corrections were used to account for multiple comparisons. The association between symptom duration and thalamic volumes was further examined in ALS and PLS patients with partial correlation, using age, gender, education and TIV as covariates. Correlations between motor disability (ALSFRS-r) and the volume of motor nuclei were also explored in PLS and ALS patients.

3. Results {#s0060}
==========

The four study groups were matched for age, gender, education and handedness. Patients groups were matched for functional disability and site of onset ([Table 1](#t0005){ref-type="table"}).Table 1The demographic and clinical profile of study participants, ECAS: Edinburgh Cognitive ALS Screen, ALSFRS-r: revised ALS functional rating scale, MND-FTD defined by the revised Strong criteria ([@b0550]).Study Groups*ALS C9+ n = 12ALS C9- n = 88PLS n = 33HC n = 117p value*Age (years)57.25 (16.454)60.18 (10.311)60.48 (10.488)57.38 (11.914)0.263Gender (male)6 (50%)56 (63.6%)19 (57.6%)56 (47.9%)0.598Education (years)12.50 (3.205)13.58 (3.169)12.88 (3.380)14.31 (3.294)0.053Handedness (right)9 (75%)81 (92%)29 (87.9%)109 (93.2%)0.185Cognitive impairment on ECAS7 (58.3%)19 (21.5%)8 (24.2%)n/a0.023Comorbid FTD as per the Strong criteria8 (66.66%)7 (7.95%)1 (3.03%)n/a\<0.01Onset (Bulbar)2 (16.66%)16 (18.18%)1 (3.03%)n/a0.102Onset (Limb)10 (83.33%)72 (81.81%)32 (96.96%)n/a0.102ALSFRS-R36.08 (7.585)36.69 (7.495)34.36 (5.337)n/a0.272

Thalamic segmentation revealed study-group specific volumetric profiles ([Fig. 2](#f0010){ref-type="fig"}). Significant atrophy was identified in the mediodorsal-paratenial-reuniens group of nuclei in all three patient cohorts. Both *C9orf72* negative ALS patients and PLS patients exhibited significant volume reductions in motor nuclei, sensory nuclei and intralaminar nuclei. *C9orf72* negative ALS patients showed additional anteroventral, medial geniculate, and lateroposterior changes compared to healthy controls. PLS patients had a distinctive thalamic signature with preferential pulvinar and lateral geniculate compared to healthy controls but also in contrast to *C9orf72* negative ALS patients ([Fig. 2](#f0010){ref-type="fig"}). While intergroup differences between hexanucleotide carriers and sporadic ALS patients did not reach significance following FDR corrections, reduced mediodorsal-paratenial-reuniens volumes were observed in hexanucleotide carriers compared to C9orf72 negative ALS patients (p = 0.085) ([Table 2](#t0010){ref-type="table"}).Fig. 2The volumetric profile of thalamic nuclei in healthy controls (HC), primary lateral sclerosis (PLS), *C9orf72* positive ALS patients (ALS-C9+), and *C9orf72* negative ALS patients (ALS-C9-) based on estimated marginal means adjusted for age, gender, total intracranial volumes (TIV) and education. Error bars represent 95% confidence intervals. Inter-group differences corrected for multiple comparisons are highlighted with asterisks \* p \< 0.05 \*\* p \< 0.01.Table 2Subcortical grey matter volumes (mm3) in healthy controls (HC), *C9orf72* positive ALS patients (ALS-C9 + ), *C9orf72* negative ALS patients (ALS-C9-) and PLS patients (PLS). Estimated marginal means and standard error are adjusted for age, gender, education and total intracranial volume (TIV). Significant intergroup differences at p \< 0.05 after FDR-correction for multiple comparisons are flagged in bold print.*NucleiStudy groupEMMStandard errorC9+ ALS vs HCC9- ALS vs HCPLS vs HCC9+ vs C9-C9+ ALS vs PLSC9- ALS vs PLS*AnteroventralHC120.3481.6060.072**0.011**0.3080.5020.3300.498ALS-C9+108.2474.985ALS-C9-112.7011.843PLS115.7163.004Lateral geniculateHC166.0021.9030.2270.378**\<0.001**0.4830.486**0.014**ALS-C9+156.1785.908ALS-C9-162.5252.184PLS149.8743.560Medial geniculateHC109.0691.2890.085**0.038**0.4830.4830.3000.498ALS-C9+99.9154.000ALS-C9-104.0131.479PLS106.4282.411Pulvinar-limitansHC1511.82912.0940.9630.680**0.011**0.8790.178**0.035**ALS-C9+1510.01237.536ALS-C9-1502.54213.880PLS1432.71622.622LaterodorsalHC23.301.6920.2120.0720.3000.6660.072**0.017**ALS-C9+19.6072.148ALS-C9-20.893.794PLS25.3441.295LateroposteriorHC112.5761.4800.142**0.037**0.6800.6050.2890.308ALS-C9+103.3044.594ALS-C9-106.6521.699PLS110.9812.769Mediodorsal-paratenial-reuniensHC952.4858.870**\<0.001\<0.001\<0.001**0.0850.4830.207ALS-C9+831.61127.532ALS-C9-895.90910.180PLS863.27216.593Motor HubHC1823.54215.4410.161**0.0070.014**0.8260.9500.670ALS-C9+1730.54847.926ALS-C9-1744.31817.721PLS1726.03928.884Sensory HubHC870.1098.9490.498**\<0.001\<0.001**0.4830.1650.227ALS-C9+844.26227.777ALS-C9-816.15810.271PLS785.38116.740IntralaminarHC407.6343.9410.609**0.0070.017**0.4840.4070.699ALS-C9+399.28512.231ALS-C9-387.1024.523PLS383.1457.371Whole thalamusHC6096.89543.0050.098**\<0.001\<0.001**0.7740.6050.212ALS-C9+5802.968133.480ALS-C9-5852.81349.356PLS5698.89680.445

4. Vertex analyses {#s0065}
==================

Vertex analyses also confirmed considerable thalamic atrophy in both ALS cohorts. In C9 + ALS patients strikingly symmetric patterns of atrophy were observed with superior-inferior predominance as well as posterior involvement. Similar patterns were noted in the C9- ALS group compared to healthy controls. The direct comparison of hexanucleotide carrying ALS patients with C9 negative patients revealed asymmetric superior-inferior-posterior atrophy in the right thalamus. Anterior and posterior deformations were observed in PLS compared to C9 negative ALS. Widespread superior, inferior and posterior shape alterations were noted in PLS compared to healthy controls ([Fig. 3](#f0015){ref-type="fig"}).Fig. 3Shape deformations in C9 positive ALS in comparison to healthy controls (1), C9 negative ALS compared to healthy controls (2), C9 positive ALS compared to C9 negative ALS (3), PLS compared to C9 negative ALS (4), and PLS patients in contrast to healthy controls (5). Average thalamic mesh is shown in blue and surface projected patterns of atrophy are shown in orange colour at p \< 0.05 corrected for age, gender, education, and TIV. Anterior, superior lateral from the right, superior lateral from the left and posterior inferior views are presented. Rt -- right, Lt. -- left. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

5. Morphometric alterations {#s0070}
===========================

Morphometric analyses revealed largely asymmetric changes. Statistically significant right posterolateral atrophy was observed in C9 negative ALS compared to healthy controls at p \< 0.05 FWE. C9 negative ALS patients exhibited left ventral lateral pathology in comparison to PLS patients at p \< 0.05 FWE. PLS patients exhibited bilateral posterior density reductions in contrast to healthy controls ([Fig. 4](#f0020){ref-type="fig"}).Fig. 4Patterns of thalamic atrophy in C9 negative ALS in comparison to healthy controls (1), in C9 negative ALS versus PLS (2) and in PLS compared to healthy controls (3). Morphometric changes are shown on an atlas-defined bi-thalamic grey matter mask (white) with corresponding p-values corrected for age, gender, total intracranial volumes and education. The colour bar indicates probability values less than 0.05.

6. Correlation analyses {#s0075}
=======================

Within the patient group (ALS, PLS), we only found a significant association between pulvinar volumes and symptom duration (r = -0.269; p~FDR~ = 0.02). The association between symptom duration and posterior-lateral geniculate volume did not survive correction for multiple comparisons (r = -0.208; p~unc~ = 0.018; p~FDR~ = 0.09). There were no direct associations between the volumes of motor nuclei and ALS functional rating scale values.

7. Discussion {#s0080}
=============

Our findings indicate phenotype-specific patterns of thalamic degeneration in MND with the preferential involvement of specific nuclei as opposed to global thalamic atrophy. The selective involvement of thalamic nuclei highlights that thalamic pathology in motor neuron diseases is not homogenous; therefore earlier efforts to evaluate the entire structure by volumetric, metabolic, shape or diffusivity measures are likely to have averaged biophysical indices across affected and unaffected regions.

One of the key objectives of the study was to assess thalamic motor nuclei in ALS. The ventral anterior nucleus contributes to planning and initiating movement, while the ventral lateral nucleus plays a role in movement modulation and coordination ([@b0565]). The majority of ALS imaging studies focus on pyramidal weakness and evaluate motor cortex, corticospinal tract, brainstem and spinal cord metrics ([@b0480], [@b0515], [@b0415], [@b0045]). Extrapyramidal motor deficits have been sporadically reported in ALS ([@b0465], [@b0175], [@b0140], [@b0005]), but ascertaining extra-pyramidal signs clinically is challenging in the presence of combined upper and lower motor neuron degeneration ([@b0320]). In this study, both *C9orf72* negative ALS patients and PLS patients exhibited significant volume reductions in thalamic motor nuclei. Extrapyramidal features of ALS are relatively under recognised despite case series ([@b0465], [@b0175], [@b0615]), gait analyses ([@b0200]), and nuclear medicine studies in both sporadic ([@b0555]) and familial cases ([@b0475], [@b0405]). Occupational therapy and physiotherapy interventions in ALS typically focus on pyramidal weakness; spasticity management for UMN dysfunction and fitting orthoses to limbs affected by LMN dysfunction. Impaired gait initiation and impaired postural reflexes however are also likely to contribute to poor mobility and increased fall risk in ALS and may benefit from targeted interventions ([@b0380], [@b0495]). Extra-pyramidal features of bulbar dysfunction are also poorly characterised; assessments and interventions typically focus on the UMN/LMN aspects of dysarthria and dysphagia ([@b0630]). We have not identified direct correlations between ALSFRS-r and motor nucleus volumes in ALS or PLS. This is not unexpected, as ALSFR-r is thought to be disproportionately representative of lower motor neuron degeneration in ALS and may be particularly suboptimal to assess motor disability in PLS ([@b0255], [@b0370], [@b0210]).

We have also identified significant volume reductions in sensory nuclei in both the *C9orf72* negative ALS cohort and in the PLS group. Sensory deficits are seldom evaluated routinely in established ALS and PLS patients, as clinical disability is dominated by relentlessly progressive limb weakness, bulbar impairment and eventually respiratory weakness. Paraesthesiae are often reported by patients but frank nociceptive, proprioceptive or thermoceptive deficits are not characteristic of ALS. Cortical imaging in ALS does not typically identify postcentral gyrus involvement ([@b0510]), but posterior column degeneration has been previously captured on spinal imaging ([@b0155]). Spinal dorsal column degeneration have been reported based on DTI and MT data ([@b0155], [@b0485]) and combined spinal DTI and neurophysiology studies suggest subclinical sensory dysfunction in ALS patients without frank sensory symptoms ([@b0260]). There is additional neurophysiological evidence that cerebral sensory processing may be affected in ALS ([@b0340], [@b0385]). Our finding of ventral posterolateral and ventral medial thalamus degeneration indicates that sub-clinical sensory deficits are likely to add to the clinical heterogeneity of the condition. Multidisciplinary rehabilitation efforts in ALS should take spinal posterior column and sensory thalamus degeneration into account when assessing gait disturbance and fall risks in ALS ([@b0380], [@b0495]).

In our study, we identified significant mediodorsal-paratenial-reuniens pathology in both PLS and ALS. Our results suggest that this group of nuclei are affected in ALS irrespective of *C9orf72* status. These nuclei play a physiological role in executive function ([@b0455], [@b0375], [@b0435]); memory consolidation ([@b0445], [@b0570]), recall ([@b0570], [@b0440]). The involvement of thalamic nuclei which mediate cognitive functions mirrors observations of widespread extra-motor cortical involvement in ALS. Both ALS and FTD studies provide ample evidence that thalamic pathology is not unique to *C9orf72* ([@b0610], [@b0070]), and it is also clear that a proportion of *C9orf72* negative sporadic ALS patients fulfil diagnostic criteria for comorbid FTD ([@b0550]). In our C9negative cohort 8% of patients had comorbid FTD and 21% had cognitive impairment based on a disease-specific screening instrument. Our findings support the notion that *C9orf72* is not the sole cause of ALS-associated cognitive impairment and that sporadic cases also exhibit extra-motor grey matter changes and cognitive impairment despite testing negative for a panel of established mutations. Cognitive deficits in ALS are typically linked to extra-motor cortical pathology and frontotemporal white matter alterations, and the contribution of subcortical grey matter degeneration to neuropsychological manifestations is seldom evaluated specifically. Neuropsychological deficits in ALS are thought to be dominated by executive ([@b0010], [@b0185]) and behavioural dysfunction ([@b0190], [@b0110]), but deficits in social cognition ([@b0100], [@b0105]) and memory impairment are also increasingly recognised ([@b0050], [@b0135]).

Intergroup volumetric differences between hexanucleotide carriers and sporadic ALS patients did not reach significance following FDR corrections in our study, but reduced (p = 0.085 FDR) mediodorsal-paratenial-reuniens volumes were observed in hexanucleotide carriers compared to *C9orf72* negative ALS patients. This observation may be a reflection of more widespread cognitive involvement in *C9orf72* carriers in comparison to C9 negative patients which is observed both clinically and on detailed neuropsychological assessment ([@b0115], [@b0530], [@b0425], [@b0195]). On vertex analyses however, C9orf72 positive patients exhibited significant superior--inferior shape deformations compared to C9negative patients. GGGGCC hexanucleotide expansions have been specifically linked to pulvinar atrophy in FTD both on imaging ([@b0075], [@b0325], [@b0330]) and post mortem ([@b0580], [@b0625]). In contrast to observations in FTD, we have not observed preferential pulvinar involvement in our sample of *C9orf72* positive ALS cohort. While the sample size of our *C9orf72* positive cohort is limited, we have observed marked pulvinar atrophy in our PLS cohort who tested negative for repeat expansions. The thalamic profile of our PLS group suggests that pulvinar atrophy is not unique to hexanucleotide repeat expansions carriers in motor neuron diseases.

*C9orf72* negative ALS patients also showed significant anteroventral changes compared to healthy controls. The physiological role of the anteroventral nucleus is primarily associated with learning ([@b0600]) and memory encoding ([@b0545]). It plays a role in episodic memory; encoding content and recollection, ([@b0335]) but has also been linked to emotional processing ([@b0360]) and executive functions ([@b0245]). Furthermore, *C9orf72* negative ALS patients exhibited marked pathology in the intralaminar nuclei which mediate a number of cognitive and sensory processes, including arousal, attention, and pain perception ([@b0275]). The involvement of anteroventral and intralaminar nuclei in *C9orf72* negative ALS is consistent with the notion that ALS is a multisystem degenerative condition involving both motor and extra-motor regions. Our findings are also support the growing body of literature that frontotemporal and subcortical grey matter changes are not unique the hexanucleotide repeat carriers in motor neuron disease ([@b0610], [@b0215]). The characterisation of the imaging features of a *C9orf72-*negative sporadic ALS cohort is clinically relevant, as they represent the majority of ALS patients presenting to clinics for diagnostic clarification, clinical follow-up and multidisciplinary management. C9negative sporadic ALS patients exhibit the same disease trajectory of relentless motor decline and respiratory compromise within 3--5 years of the diagnosis as those ALS patients carrying established mutations. The involvement of thalamic nuclei mediating cognitive functions therefore highlights the importance of also screening for cognitive deficits in this cohort. Cognitive deficits in ALS have widespread ramifications and may impact on compliance with assistive interventions, adherence to therapy, end-of life decisions, caregiver burden, resource allocation, and pharmacological trial participation ([@b0410]).

Our findings suggest that PLS has a distinctive thalamic signature with preferential pulvinar and lateral geniculate involvement compared to *C9orf72* negative ALS patients. These observations are consistent with the view that PLS has a number of unique, phenotype-specific imaging features, distinct from ALS. The lateral geniculate not only relays retinofugal information to the visual cortex ([@b0595]) it is also thought to contribute to visuospatial filtering and perception ([@b0525]). Pulvinar-limitans volume reductions in PLS were more marked than those observed in *C9orf72* negative ALS. Posterior pulvinar thalamic regions play a role in maintaining attention to visual stimuli ([@b0540]), and pulvino-cortical projections are also associated with attention modulation, working memory, and decision making ([@b0280]). The involvement of the motor nuclei, sensory nuclei and the mediodorsal-paratenial-reuniens region in PLS are comparable to the sub-thalamic profile of *C9orf72* negative ALS. Focal pathological changes in sensory thalamus regions have not been previously reported in PLS. The involvement of ventral anterior and ventral lateral nuclei in PLS, which mediate movement initiation and modulation, are relatively novel findings as extrapyramidal dysfunction is not well established in PLS. It is noteworthy that thalamic pathology is thought to contribute to the development pseudobulbar affect ([@b0310]) which has a particularly high prevalence in PLS. Our findings therefore complement the emerging literature of extra-pyramidal and extra-motor deficits in PLS ([@b0150], [@b0170], [@b0165]).

Post-mortem histopathology findings in ALS are seldom reported in conjunction with ante mortem neuroimaging findings ([@b0270], [@b0350]) and existing imaging studies have not elaborated on post-mortem thalamus pathology. Studies of pathological TDP-43 patterns in ALS have consistently reported thalamic involvement ([@b0240]), but the vulnerability of specific thalamic nuclei are poorly characterised. Data from large case series ([@b0090]) suggest the preferential involvement of large thalamic relay neurons projecting to layer IV of the neocortex which is associated with Stage 2 of a corticofugal pTDP-43 model ([@b0085]). Few post-mortem studies have specifically evaluated thalamic changes in the ALS spectrum and many of these are case reports or case-series ([@b0235]). The paucity of post mortem thalamus studies in ALS is in sharp contrast to FTD, where thalamic changes have been comprehensively evaluated in patients stratified for clinical phenotypes ([@b0160]) and specific genotypes ([@b0580], [@b0625]). Presymptomatic imaging studies have consistently highlighted thalamic pathology before disease manifestation ([@b0330], [@b0460], [@b0060], [@b0420]) but there is a lack of consensus regarding propagation biology in ALS. While the controversy around corticofugal versus corticopetal spread persists, transneuronal processes and microglial inflammation are established mechanisms of disease propagation in ALS. Imaging studies in ALS have played a limited role in clarifying underlying molecular processes, but they have repeatedly noted the concomitant degeneration of structurally or functionally interconnected brain regions ([@b0585], [@b0020]). As the thalamus relays a multitude of corticoefferent and corticoafferent connections, its selective involvement in ALS mirrors the widespread cerebral and spinal cord alterations associated with the condition.

Global thalamus pathology has been previously investigated in ALS by a multitude of techniques including VBM, total volumes, texture analysis, spectroscopy, TBSS, PET, fMRI and parcellation based on cortical connectivity. In this study we have primarily focused on the volumetric characterisation of thalamic nuclei, but supplementary vertex and morphometric analyses were also carried out. Relatively limited concordance was identified between regional volume reductions, shape deformations and morphometric changes. While anatomical segmentation revealed selective nuclear atrophy, vertex analyses only showcased overall shape deformation without providing specific information on which nuclei were driving these changes. This highlights the relative limitation of evaluating surface-projected vertex changes alone in structures which consist of multiple sub-regions with potentially varying vulnerability to ALS. Our findings also highlight the limitations of assessing total thalamic volumes in MND phenotypes. Total thalamus volume reduction did not reach significance in the *C9orf72* positive cohort compared to controls, but the assessment of medidorsal-paratenial nuclei revealed marked volume reductions in hexanucleotide carriers. Furthermore, while total thalamus volumes were similarly reduced in C9negative ALS and PLS, their nuclear profiles are distinctly different; the laterodorsal nuclei were preferentially affected in C9negative ALS and the pulvinar region in PLS.

This study has a number of limitations. Consistent with the population-based incidence of *C9orf72* in ALS, the cohort size of C9 + ALS group is limited which precludes conclusive genotype-associated observations. The inclusion of a non-MND disease-control group with an alternative neurodegenerative diagnosis, such as AD or FTD would have supported the specificity of our thalamic findings to ALS and PLS. We have focused on descriptive analyses and not explored direct clinico-radiological correlations between neuropsychological measures and imaging findings ([@b0590]). Cognitive functions and behavioural regulation are mediated through function-specific multi-synaptic cortico-basal circuits ([@b0400]) and therefore seeking direct associations between clinical measures and focal thalamic indices would overlook the contribution of other white and grey matter components to clinical performance. Post mortem histopathology data or ex-vivo MRI would have provided important validation for the radiological observations made in vivo ([@b0040]). A limitation of our supplementary morphometric analysis is that it used labels from a different atlas than the one utilised for anatomical segmentation. Finally, while our data provides a snapshot of thalamic alterations in ALS, a robust multi-timepoint design would have provided crucial longitudinal insights ([@b0130], [@b0505]). Notwithstanding these limitations, our data provide evidence of focal thalamic involvement in ALS and PLS and demonstrate the utility of appraising thalamic nuclei individually instead of evaluating overall thalamic changes.

8. Conclusions {#s0085}
==============

We have detected phenotype-specific patterns of focal thalamic pathology in ALS and PLS. The characterisation of thalamic pathology allows the identification of the most vulnerable group of nuclei, the measures of which are superior biomarkers candidates than indices of the entire structure. The pathology of thalamic nuclei mediating sensory, cognitive and behavioural functions support the conceptualisation of ALS and PLS as multi-system conditions. The thalamic profiles of ALS and PLS provide anatomical evidence of extra-pyramidal motor and sensory involvement in these conditions.
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